Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stupak will retire

This article was originally published in The Tan Sheet

Executive Summary

House Oversight and Investigations Subcommittee Chairman Bart Stupak, an 18-year member of Congress and a frequent critic of FDA's record for food and drug safety, says he will not seek reelection. At an April 9 press conference at his congressional district in Michigan, the Democrat said he has served the public more than 30 years, beginning as a police officer in Escanaba, Mich., and later as a State Police trooper, before becoming a state representative and later a member of Congress. Like his recognized mentor, fellow Michigan Democrat John Dingell, Stupak said health care reform was a priority for him from the beginning, and stressed the significance of the recent passage of reform legislation (1"The Tan Sheet" March 29, 2010). "I've worked alongside my colleagues to achieve health care reform and I'm proud to have helped bring it across the finish line," he said, adding, "I felt that my main legislative goal was accomplished." Potential candidates have until May 11 to file to campaign for the office

You may also be interested in...



Health Reform Opens NRT Coverage In 2014, Hamstrings OTC HSA Eligibility

The health care reform law now enacted significantly restricts health savings and flexible spending account eligibility for OTC drugs, allowing reimbursement only of nonprescription drugs prescribed by a doctor

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS104000

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel